Skip to content

REGENERON PHARMACEUTICALS, INC.

Follow

13F filer, CIK 872589, TARRYTOWN, NY

REGENERON PHARMACEUTICALS, INC. reported $179,631,814 across 3 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-05.

Accepted , ingested 13F-HR 0001104659-26-123321

Period
2026-09-30
Reported value
$180M
Holdings
3
Top 10 weight
100%
New
0
Sold out
0

Holdings, Q3 2026

Share positions as resolved from 13F-HR 0001104659-26-123321, largest first. % of portfolio is the value over $179,631,814, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
PBLSPARABILIS MEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 4,166,666 shares; 2026Q3: 4,166,666 shares 4,166,666$135M74.9%0Timeline
NTLAINTELLIA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 3,702,995 shares; 2025Q1: 3,702,995 shares; 2025Q2: 3,702,995 shares; 2025Q3: 3,702,995 shares; 2025Q4: 3,702,995 shares; 2026Q1: 3,702,995 shares; 2026Q2: 3,702,995 shares; 2026Q3: 3,702,995 shares 3,702,995$44.7M24.86%0Timeline
ACETADICET BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 60,511 shares; 2026Q3: 60,511 shares 60,511$432K0.24%0Timeline

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001104659-26-123321 base2026-11-05